NQO1 and neoplasm: Since bone marrow toxicity is often the dose limiting toxicity for bioreductive agents, an agent that is fully activated by the level of NQO1 in the tumor but is not activated by the level of NQO1 in bone marrow cells would produce little bone marrow toxicity and would have the highest therapeutic index.